Dr. Bill Williams, President and CEO BriaCell Therapeutics Corp. (“BriaCell”) (BCT.V) (BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, called in to SmallCapVoice.com, Inc. to discuss some of the recent news and highlights for the company. Recently the Company announced that Sylvester Comprehensive Cancer Center at the University of Miami is now actively screening and enrolling patients in the ongoing, multicenter, Phase IIa study of Bria-IMT™ in advanced breast cancer. Another validation of the Company’s work came through its presentations at the 2018 American Association of Cancer Research (AACR) Annual Meeting.
This interview may include forward looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. SmallCapVoice.com, Inc. received 2,500 from the company on 4-2-18 for 30 days of service.